| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Tempest Therapeutics Inc reports results for the quarter ended in March - Earnings Summary | 4 | Reuters | ||
| Do | Tempest Therapeutics: Tempest Reports First Quarter 2024 Financial Results and Provides Business Update | 56 | GlobeNewswire (Europe) | Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual MeetingPublished... ► Artikel lesen | |
| Do | Tempest Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| Do | Tempest Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.04. | Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 115 | GlobeNewswire (Europe) | BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| 09.04. | Tempest Therapeutics: Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting | 12 | GlobeNewswire (USA) | ||
| 04.04. | Tempest Therapeutics: Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications | 156 | GlobeNewswire (Europe) | TPST-1120, a first-in-class, oral, selective PPAR? antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data... ► Artikel lesen | |
| 20.03. | Tempest Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 20 | Reuters | ||
| 19.03. | Tempest Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 4 | SEC Filings | ||
| 19.03. | Tempest Therapeutics GAAP EPS of -$1.91 beats by $0.03 | 3 | Seeking Alpha | ||
| 19.03. | Tempest Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | Tempest Therapeutics: Tempest Reports Year End 2023 Financial Results and Provides Business Update | 128 | GlobeNewswire (Europe) | Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in two... ► Artikel lesen | |
| 19.03. | Tempest Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.03. | Tempest Therapeutics: Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting | 21 | GlobeNewswire (USA) | ||
| 02.02. | Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 426 | GlobeNewswire (Europe) | BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted... ► Artikel lesen | |
| 05.01. | Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 259 | GlobeNewswire (Europe) | BRISBANE, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted... ► Artikel lesen | |
| 01.12.23 | Tempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 682 | GlobeNewswire (Europe) | BRISBANE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted... ► Artikel lesen | |
| 20.11.23 | Tempest Therapeutics: Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference | 41 | GlobeNewswire (USA) | ||
| 17.11.23 | Tempest Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 12 | SEC Filings |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 1.716 |
| TUI | 1.228 |
| BAYER | 1.227 |
| NEL | 1.144 |
| SIEMENS ENERGY | 976 |
| NVIDIA | 741 |
| MERCEDES-BENZ | 721 |
| RHEINMETALL | 716 |
| DEUTSCHE BANK | 622 |
| PLUG POWER | 607 |
| BYD | 549 |
| NOVAVAX | 546 |
| RWE | 525 |
| PALANTIR TECHNOLOGIES | 501 |
| VOLKSWAGEN | 493 |
| ALLIANZ | 487 |
| K+S | 465 |
| COMMERZBANK | 456 |
| AIXTRON SE | 435 |
| TESLA | 420 |
| BASF | 415 |
| DEUTSCHE LUFTHANSA | 415 |
| THYSSENKRUPP | 399 |
| NORDEX | 377 |
| ALIBABA | 371 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
